| Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information. |
| |
| Device | VENTANA PD-L1(SP142) Assay. |
| Generic Name | Immunohistochemistry assay, antibody, programmed death-ligand 1 |
| Applicant | Ventana Medical Systems, Inc. 1910 E. Innovation Park Dr. Tucson, AZ 85755 |
| PMA Number | P160002 |
| Supplement Number | S009 |
| Date Received | 09/14/2018 |
| Decision Date | 03/08/2019 |
| Product Code |
PLS |
| Docket Number | 19M-1310 |
| Notice Date | 03/20/2019 |
| Advisory Committee |
Pathology |
| Clinical Trials | NCT02425891
|
| Supplement Type | Panel Track |
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval for VENTANA PD L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD L1 clone SP142. The device is intended for use in the assessment of the programmed death-ligand 1 (PD-L1) protein in tumor cells and tumor-infiltrating immune cells in the formalin-fixed, paraffin-embedded (FFPE) tissues indicated below stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a VENTANA BenchMark ULTRA instrument. Determination of PD-L1 status is indication-specific, and evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity.VENTANA PD-L1 (SP142) Assay is indicated as an aid for identifying patients for treatment with the therapies for the respective cutoffs listed in Table 1 in accordance with the approved therapeutic product labeling. Table 1. Companion diagnostic indications for the VENTANA PD-L1 (SP142) Assay Indication for use Therapy Cutoff Urothelial Carcinoma TECENTRIQ >= 5% ICTriple-Negative Breast Carcinoma (TNBC) TECENTRIQ >= 1% ICPD-L1 expression in >= 50% TC or >= 10% IC determined by VENTANA PD-L1 (SP142) Assay in non-small cell lung cancer (NSCLC) patients may be associated with enhanced overall survival from TECENTRIQ (atezolizumab).This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls. This product is intended for in vitro diagnostic (IVD) use. |
| Approval Order | Approval Order |
| Summary | Summary of Safety and Effectiveness |
| Labeling | Labeling
|
|
|